Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs Nucleic Acid Testing Markets in Malaysia (2005-2010)
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

Nucleic Acid Testing Markets in Malaysia (2005-2010)

DateMay, 2006
Pages0
Price / format€4897 / Hard Copy
€4520 / Site License
€5650 / Enterprisewide

€4 483 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 This Frost & Sullivan research service entitled Nucleic Acid Testing Markets in Malaysia gives an overview of the current status of the nucleic acid testing market in Malaysia and discusses present and potential revenues. The study also discusses the prevailing industry challenges and gives an overview of the reimbursement system and regulatory environment for NAT in Malaysia.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

- Polymerase Chain Reaction (PCR)

- RT-PCR

- Other Platforms

Technologies

The following technologies are covered in this research:

- Nucleic Acids: Various high molecular weight acids, such as DNA and RNA, found in all living cells as well as viruses and made up of nucleotide chains, which carry genetic information.
- Nucleic Acid Testing (NAT): Nucleic acid-based amplification test.
- Polymerase Chain Reaction (PCR): A revolutionary technology, which generates multiple copies of a specific nucleotide sequence from a target organism and able to detect trace elements of target organisms with high specificity. Applications include biological research, clinical diagnostics, forensics, and genetics.
- RT-PCR: Real-time measurement for PCR, through quantitative detection of specific nucleic acid sequences and permits accurate and informative measurements for DNA or RNA quantification. Real-time applications include measuring gene expression and detecting bacterial or viral load within samples.
- bDNA: Amplified detection of minute quantities of genetic material (DNA or RNA) and direct quantification of virus in serum or plasma. Distinct from PCR due to the measurement of the virus present through amplification of signals, rather than target sequences.
- Enzyme-linked Immunosorbent Assay (ELISA): Detection and measurement of an immune response in a solution. The presence of antigens or antibodies is verified and visualized with an application of tagged antibodies. It is generally less sensitive than nucleic acid-based amplification techniques.
- Ligase Chain Reaction (LCR): A technique for the detection of any defined DNA sequence by amplification of ligation products complementary to the target sequence. Similar to PCR, this method allows the detection of minute levels of known nucleic acid sequences.
- Nucleic Acid Sequence-based Amplification (NASBA): Alternative to PCR, whereby RNA or DNA is selectively amplified through continual amplification at a constant temperature.
- Strand Displacement Amplification (SDA): In contrast to other techniques, which rely on thermal cycling, SDA is an isothermal process (entire reaction is performed at a uniform temperature) that employs a series of primers, DNA polymerase, and a restriction enzyme to exponentially amplify the target nucleic acid sequence.
- Transcription Mediated Amplification (TMA): An isothermal RNA transcription amplification technique employing RNA polymerase and reverse transcriptase to drive the reaction. TMA can amplify either DNA or RNA, producing an RNA amplicon, in contrast to most other nucleic acid amplification methods that only produce DNA.
- Point-of-care Testing (POCT): Pathology investigation by or on behalf of the treating medical practitioner on-site. It is a diagnostic testing conducted close to the site where clinical care is delivered.
- Automation: Laboratory automation can be defined broadly as any device, software, or process that improves the efficiency of the laboratory.
- Integration: The act of integrating various automated tasks into a continuous process.

Market Overview

Healthcare Challenges among Growing Asian Economies help Create Growth Opportunities
The boom in economic growth among Asian countries is leading to considerable inequalities in healthcare provisions. In addition to the challenges of a rapidly increasing aged population, healthcare systems across the region are being confronted with the looming danger of infectious diseases As a result, there is an increasing need for fast and specific diagnosis and confirmation of diseases in order to control potential epidemics. This is paving the way for increased growth of the nucleic acid testing (NAT) markets in Asia. The threat of emerging infectious diseases such as avian flu and increasing disease burdens of HIV and tuberculosis are critical contributing factors to the growth opportunities in the NAT markets.
Conventional diagnostic methods such as cell culture, antibody testing, and even symptomatic diagnosis consume considerable time as compared to NAT. A polymerase chain reaction (PCR) test only takes 30 minutes to deliver results. It also requires minimal staff training and expertise due to its simple operations. Furthermore, data is verified with the included set of standards and a positive and negative control may also be further added. Constant improvements in technology have made NAT comparable to dip-sticks on the time front, thus making it a favored method of diagnosis, explains the analyst of this research service. In terms of sensitivity and specificity, NAT has a clear advantage over conventional immunoassay or serotyping, as it is not dependent on the operators personal judgment, and these inherent advantages are proving to be strong drivers for their increasing adoption throughout the region.

Increased Incidence and Prevalence of Infectious Disease Encourage the Adoption of NAT Technology
Since the severe acute respiratory syndrome (SARS) epidemic and the food poisoning due to Norovirus in January 2004, a lot of attention has been focused on NAT methods in Singapore. For example, during the dengue epidemic in 2005, the healthcare industry had resorted to using NAT with promising outcomes. The SARS epidemic also provided an entry point for the increased penetration of NAT technology into the markets in China and Hong Kong, where research projects are primarily focused on the study of infectious diseases using NAT. In Malaysia, viral and bacterial diseases are the key revenue drivers for the NAT market and dengue fever, tuberculosis, HIV, and viral hepatitis were the diseases with highest incidences in 2005.
Considering the limitation in funding as well as the transition time needed to fully adopt NAT into existing practices, the overall NAT market in Asia Pacific is likely to grow at a medium pace. Although initial adoption of the technology in the medical community has been slow, NAT is slowly but definitely becoming a recognized and preferred diagnostic tool, says the analyst. Additionally, an increase in research employing molecular biology related protocols is also driving the demand for more NAT-related technologies in Asia.










Table of contents:
 1. Research and Market Overview

- 1. Research Overview

- - 1. Research Scope and Methodology

- - 2. Market Segmentation

- - 3. Glossary of Terms

- 2. Market Overview

- - 1. Disease Profile

- - 2. Overview of the Malaysian NAT market

- - 3. Market Drivers-- a. More Participation from Private Healthcare Providers-- b. High Incidence Rate of Infectious Disease-- c. Change in Disease Profile - Increase in Public Awareness Level-- d. Demand of People for Better Medical Services- Increased Healthcare Expenditure-- e. Ageing Population-- f. Advance in Nucleic Acid Testing Technology

- - 4. Market Restraints-- a. High Medica Techonolgy Cost Affecting the Adoption Rate-- b. Shortage of Skilled Laboratory Personnel-- c. Synachronization Among Scientist and Industrial Players – Lack of Interaction-- d. Limited Healthcare Facilities in Rural Area-- e. Reimbursement for Healthcare Services is Still Low

- 2. Reimbursement Structure in Malaysia

- 1. Overview of the Reimbursement in Malaysia

- - 1. Status of Medical Reimbursement in Malaysia

- 3. Market Engineering Measurements

- 1. Market Analysis

- - 1. Market Engineering Measurements

- - 2. Market Size

- - 3. Market Revenue Forecasts

- - 4. Market Age

- - 5. Pricing Trends

- - 6. Future Potential of NAT

- 2. End-User Analysis

- - 1. Number of Customer Sites

- - 2. Customer Loyalty

- 3. Distribution Structure Analysis

- - 1. Distribution Channel

- 4. Competitive Analysis

- - 1. Introduction

- - 2. Product Mix and Market Share

- - 3. Competitors' Profiles

- 4. Research Activities

- 1. Nucleic Acid Testing in Research Activities

- - 1. Research in Academic Institutions

- 5. Conclusion

- 1. Strategic Recommendations

- - 1. Short Term Recommendation

- - 2. Long Term Recommendations

- 6. Frost & Sullivan Awards

- 1. Frost & Sullivan Awards for Nucleic Acid Testing Markets in Asia

- - 1. Customer Service Leadership Award

- - 2. Technology Innovation Award

- - 3. Vertical Market Penetration Leadership Award

- - 4. Competitive Strategy Leadership Award

- 7. Appendix

- 1. Appendix

- - 1. Total Population in Malaysia

- - 2. Incidence and Mortality Rates of Communicable Diseases in Malaysia

- - 3. Healthcare Facilities in Malaysia

- - 4. Healthcare Budget in Malaysia

- - 5. Immunization Coverage in Malaysia

- - 6. Categories of Research Areas in Malaysia

List Of Figures

Chapter 1

- Nucleic Acid Testing Markets: Number of Cases of Notifiable Communicable Diseases (Malaysia), 2005

- Nucleic Acid Testing Markets: Market Drivers Ranked in Order of Impact (Malaysia), 2006-2010

- Nucleic Acid Testing Markets: Market Restraints Ranked in Order of Impact (Malaysia), 2006-2010

Chapter 3

- Nucleic Acid Testing Markets: Revenue Forecasts (Malaysia), 2004-2010

- Nucleic Acid Testing Markets: Pricing Profile (Malaysia), 2005-2010

- Nucleic Acid Testing Markets: Pricing Profile for Commercial Molecular Tests (Malaysia), 2005

- Nucleic Acid Testing Markets: Distribution Channel for Major Market Participants (Malaysia), 2005

- Nucleic Acid Testing Markets: Distribution Channel Structure for the Major Manufacturers (Malaysia), 2005

- Nucleic Acid Testing Markets: Competitive Structure (Malaysia), 2005-2010

- Nucleic Acid Testing Market: Key Products Offered by Major Industrial Players (Malaysia), 2005-2010

Chapter 4

- Nucleic Acid Testing Markets: Types of Research in Malaysia, 2005

Chapter 7

- Nucleic Acid Testing Markets: Total Population (Malaysia), 2004

- Nucleic Acid Testing Markets: Incidence Rate and Mortality Rate of Communicable Diseases per 100,000 Population (Malaysia), 2004

- Nucleic Acid Testing Markets: Health Facilities (Malaysia), 2004

- Nucleic Acid Testing Markets: Financial Allocation (Malaysia), 2004

- Nucleic Acid Testing Markets: Childhood Immunisation Coverage (Malaysia), 2004

- Nucleic Acid Testing Markets: Categories of Research Project to be Implemented (Malaysia), 2005

List of Charts

Chapter 1

- Nucleic Acid Testing Markets: NAT Assays Break up for Different Disease Type (Malaysia), 2004

- Nucleic Acid Testing Markets: Segmentation of Molecular Test Markets (Malaysia), 2005

Chapter 3

- Nucleic Acid Testing Markets: Market Engineering Measurements (Malaysia), 2005

- Nucleic Acid Testing Markets: Market Size in Terms of Sales Revenues (Malaysia), 2005

- Nucleic Acid Testing Markets: Revenues Forecast (Malaysia), 2004-2010

- Nucleic Acid Testing Markets: Distribution Channel Structure for the Major Players (Malaysia), 2005

- Nucleic Acid Testing Markets: Market Share Analysis (Malaysia), 2005

Chapter 4

- Nucleic Acid Testing Markets: Budget Allocation for IRPA in the 8MP (Malaysia), 2005




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com